Knowledge and attitudes toward cancer clinical trials: a multi-national cross-sectional study in the Middle East and North Africa Authors: Israa Ahmed Qutob, Abdullrahman Elgarawany, Hoda Aufy, Asmaa Soliman, Baraa M.Ayesh, Ahmed Abdelaziz Eldaly, Sally Muhamed Seliem, Rayhana Trabelsi, Farah Tarek Shaalan, Fatema Shehab, Ali Salah Elgahamy, Rola Nail Marie, Ahmed I. S. Alnatsha, Farah Mohamed Ismail Hamdan, Abd El-Rahman Shaltout, Qais AlNjoom, Fatema Ebrahim Hamza, Noor Zakareya Isa, Mujtabi Reyadh Ali Aljamri, Engy Mohamed Flifel, Kassab Kenza, Fathia Bougafa, Siham Mohamed Abdi, Saja E. Abusabha, Yasmeen Adawi, Malak Hameda, Hadeel Khaled Albaoni, Abdulrazak Baroudi, Esraa Awad, Noha Osman Frere Published: 2026 ABSTRACT BackgroundClinical trials (CTs) play a crucial role in developing new cancer treatments and enhancing patient outcomes. However, being part of these trials remains low across many regions, including the middle east and north Africa region (MENA). This study aims to evaluate the knowledge and attitudes of the general population regarding cancer clinical trials and to examine determinants of limited awareness and unfavorable attitudes.MethodsA multinational cross-sectional study was conducted from March 1 to May 31, 2024, initially involving 5,528 participants, with a final sample of 5,422 respondents after data cleaning. Data was collected using a standard population-based cross-sectional survey, distributed both online via Google Forms and in-person. Convenience sampling was employed, with Countries and centers were selected based on accessibility, willingness to participate, and representation of different healthcare systems across the MENA region. Data analysis was conducted using Jamovi 2.3.28 software.ResultsOf the 5,422 responses, significant participation was observed from Egypt (22.9%) and Bahrain (20.9%). Knowledge of CTs was moderate overall, with 63.5% of participants being familiar with the concept; however, only 9.1% exhibited a high level of knowledge. Attitudes toward CT participation were largely unfavorable, with 83.8% of respondents expressing reluctance to participate, despite 77.6% indicating an interest in receiving more information about CTs. Multinomial logistic regression indicated that private and governmental employees had higher knowledge levels compared to unemployed individuals(OR = 1.65, p = 0.007, and OR = 1.87, p < 0.001, respectively). Participants with chronic illnesses and those with prior research participation also demonstrated high knowledge(OR = 2.92, p < 0.001). Attitude scores, on the other hand, were significantly correlated with age and gender (p < 0.003). Sperman’s revealed a positive correlation between knowledge and attitude indicating that higher knowledge levels are associated with more favorable attitudes.ConclusionThis study provides insights into the general knowledge and attitude toward cancer clinical trials among the MENA population while identifying significant gaps in understanding and willingness to participate. The findings highlight the necessity of targeted educational interventions and public awareness campaigns to enhance knowledge about clinical trials and encourage a more favorable attitude toward participation. Introduction In 2020, cancer was the predominant cause of mortality for approximately 10 million individuals globally [1]. As of 2022, the lifetime probability of developing cancer was 1 in 5, accompanied by a mortality rate of 146 per 100,000 individuals. The World Health Organization (WHO) anticipates that by 2050, new cancer cases will escalate to 35 million, representing a 77% increase from the 20 million cases projected for 2022 [2]. The alarming rise in cancer incidence is particularly concerning in the middle east and north Africa regions(MENA), where the escalating prevalence of cancer in the Arab world is a growing challenge [3]. Every year, new therapeutic approaches and protocols are developed in the field of cancer therapy. Oncology is progressing as a result of developments in treatment and technology aimed at improving the care of cancer patients. In this process, clinical trials (CTs) are essential for assessing new medications, cutting-edge radiation or surgical treatments, specialized therapeutic approaches, and cutting-edge strategies like gene therapy. Unger et al.'s research found a direct correlation between a patient's participation in clinical trials and their longer survival and lower mortality [4, 5]. These studies make it easier to evaluate and contrast novel behavioral, surgical, or medical therapies. CTs are critical to improving healthcare systems because they establish guidelines and validate therapies for cancers for whom there were previously insufficient options. Trials can involve a large number of participants, and the information acquired on safety, efficacy, and side effects can be utilized to assess if the new drug improves patient outcomes [6, 7]. Countries—particularly those in the MENA region—need to fortify their healthcare systems to provide their people with cutting-edge treatments to ensure quick access to this technology. Numerous studies have highlighted the challenges faced in advancing clinical trial programs and the increasing need for health organizations to address these issues, particularly considering slow progress and persistent health inequalities. A study conducted in Saudi Arabia found low awareness levels among the general population, with significant misconceptions about the purpose and ethical oversight of clinical trials [8]. Similarly, research in Jordan among medical residents identified gaps in knowledge and uncertainty regarding trial participation, reinforcing the need for educational interventions [9]. The delayed progress can be attributed to multiple factors, including limited financial resources, ethical and legal barriers, and an underdeveloped research environment. However, patient knowledge and understanding of clinical trial research remain critical determinants in addressing these challenges [10]. This study aims to evaluate the knowledge and attitudes of the general population regarding cancer clinical trials and to examine determinants of limited awareness and unfavorable attitudes. Methods Study design and participants This cross-sectional survey was conducted from March 1 to May 31, 2024, to evaluate public awareness about cancer clinical trials among the general population in the Middle East, utilizing both online and in-person data collection methods. The required sample size was determined using the OpenEpi online calculator, assuming a prevalence of 50%. This conservative estimate is widely adopted when the true prevalence is unknown, as it provides the maximum sample size requirement. Using a 95% confidence interval (CI) and a 5% margin of error, the minimum required sample size was calculated to be 384 participants [11]. To enhance the study’s reliability and generalizability, we increased the sample size beyond this minimum to account for potential non-responses, incomplete data, and to improve the precision of our estimates. Data collection The adapted questionnaire, derived from validated sources, was translated into Arabic using a back-translation method to ensure linguistic precision and cultural relevance [12–15]. The final Arabic version of the questionnaire was developed through a structured process involving literature review, expert consultation, and pilot testing. It was pilot tested on a sample of 200 randomly selected participants balanced by gender and educational level, recruited from outpatient clinics and community centers using simple random sampling to ensure representativeness. The pilot study assessed clarity, cultural appropriateness, and reliability of the instrument, with a Cronbach’s alpha of 0.78, indicating acceptable internal consistency. Data were collected through a dual-mode approach combining face-to-face administration and online dissemination. In-person data collection was conducted in outpatient clinics, universities, and community centers, where participants completed the questionnaire on electronic tablets under the supervision of trained data collectors. Simultaneously, an online version was distributed via Google Forms through institutional mailing lists and social media platforms to reach a broader audience. All participants were informed about the study objectives and provided written or electronic informed consent prior to participation. The survey was designed to be concise and user-friendly, requiring less than seven minutes to complete. The final questionnaire comprised three main sections. The first section captured sociodemographic data, including age, gender, and educational level. The second section assessed knowledge regarding cancer clinical trials and consisted of 12 multiple-choice questions addressing understanding of trial purpose, ethical considerations, and participant rights. Each correct response was scored as one point, while incorrect or “not sure” responses were scored as zero. The third section evaluated attitudes toward participation in cancer clinical trials through nine statements rated dichotomously as favorable (1 point) or unfavorable/uncertain (0 points). The scoring key for both knowledge and attitude domains was derived from existing validated tools and refined through expert consensus. To facilitate interpretation, the total scores for knowledge and attitude were converted to percentages on a scale from 0 to 100%. Based on Bloom’s modified cut-off points, the results were classified into three levels: high (≥ 80%), moderate (60–79%), and low (< 60%). This categorization method is widely applied in health-related knowledge, attitude, and practice (KAP) studies and allows for standardized comparison across different populations. The final data were entered, verified, and analyzed exclusively by the principal investigators to maintain accuracy and confidentiality [12, 16]. Statistical analysis Statistical analysis was conducted using Jamovi 2.3.28 software to assess the level of knowledge and attitude toward cancer clinical trials among the general population. Descriptive statistics were used to summarize sociodemographic characteristics. The chi-square test was performed to examine associations between categorical demographic variables and levels of knowledge and attitude. Logistic regression analysis was conducted to identify potential predictors influencing knowledge and attitude. Additionally, a Spearman correlation test was utilized to evaluate the relationship between knowledge and attitude. All results were reported with 95% confidence intervals, and a p-value of < 0.05 was considered statistically significant. Results A total of 5,422 responses from the MENA region's general population were included in this study. The majority of responses were from Egypt (22.9%) and Bahrain (20.9%). Most respondents were between 18–30 years old (65.38%), female (62%), unmarried (61.3%), and had a university degree or higher (81.5%). Additionally, 76.8% of participants had never previously participated in research. The detailed demographic features of the study population are presented in Table 1.Table 1Sociodemographic characteristics of participants in the MENA Region (n = 5,442)variablesNumber (percentage)Age18–30 years3545 (65.4%)31–40 years895 (16.5%)41–60 years877 (16.2%) > 60 years105 (1.9)GenderFemale3363 (62%)Male2059 (38%)Marital statusUnmarried3326 (61.3%)Married2096 (38.7%)OccupationUnemployed953 (17.6%)Student1961 (36.2%)Private work1249 (23%)Government work1259 (23.2%)Education levelUneducatedSecondary or lessUniversity or more82 (1.5%)923 (17%)4417 (81.5%)Monthly incomeNo income1627(30%)Middle income2222 (41%)High income1573 (29%)Presence of any Chronic diseaseYes1003 (18.5%)No4419 (81.5%)Previous participation in researchYes1259 (23.2%)No4163 (76.8%)CountryEgypt1241 (22.9%)Palestine279 (5.1%)Bahrain1135 (20.9%)Libya298 (5.5%)Qatar431 (7.9%)Sudan102 (1.9%)Saudi Arabia729 (13.4%)The UAE104 (1.9%)Moroco555 (10.2%)Kuwait135 (2.5%)Lebanon19 (0.4%)Oman133 (2.5%)Somalia22 (0.4%)Syria25 (0.5%)Tunisia18 (0.3%)Jordon111 (2%)Yemen19 (0.4%)Iraq46 (0.8%)Algeria20 (0.4%) Table 1Sociodemographic characteristics of participants in the MENA Region (n = 5,442)variablesNumber (percentage)Age18–30 years3545 (65.4%)31–40 years895 (16.5%)41–60 years877 (16.2%) > 60 years105 (1.9)GenderFemale3363 (62%)Male2059 (38%)Marital statusUnmarried3326 (61.3%)Married2096 (38.7%)OccupationUnemployed953 (17.6%)Student1961 (36.2%)Private work1249 (23%)Government work1259 (23.2%)Education levelUneducatedSecondary or lessUniversity or more82 (1.5%)923 (17%)4417 (81.5%)Monthly incomeNo income1627(30%)Middle income2222 (41%)High income1573 (29%)Presence of any Chronic diseaseYes1003 (18.5%)No4419 (81.5%)Previous participation in researchYes1259 (23.2%)No4163 (76.8%)CountryEgypt1241 (22.9%)Palestine279 (5.1%)Bahrain1135 (20.9%)Libya298 (5.5%)Qatar431 (7.9%)Sudan102 (1.9%)Saudi Arabia729 (13.4%)The UAE104 (1.9%)Moroco555 (10.2%)Kuwait135 (2.5%)Lebanon19 (0.4%)Oman133 (2.5%)Somalia22 (0.4%)Syria25 (0.5%)Tunisia18 (0.3%)Jordon111 (2%)Yemen19 (0.4%)Iraq46 (0.8%)Algeria20 (0.4%) Sociodemographic characteristics of participants in the MENA Region (n = 5,442) Uneducated Secondary or less University or more 82 (1.5%) 923 (17%) 4417 (81.5%) Regarding knowledge and attitude-related responses, 63.5% of participants had heard of clinical trials (CTs). However, 66.7% were unfamiliar with ethics review committees, while 73.9% were aware of the Food and Drug Administration (FDA). A significant portion of the participants (89.9%) perceived a benefit to the community from CTs, though 61.5% believed there was no direct benefit to the individual participants. Over two-thirds (71.4%) supported testing an already approved drug on patients, but an equal proportion (71.4%) were opposed to testing a new, experimental, non-approved drug. Although 83.8% of participants were hesitant to participate in CTs themselves, 77.6% expressed a desire to learn more about CTs. Detailed responses are available in Tables 2 and 3.Table 2Participants’ knowledge of clinical trials: response distribution and accuracy (n = 5,442)ItemsNumbers(N)Percentage (%)Have you ever heard about clinical trials (CT)?YesNO3445197763.536.5Definition of a CTCorrect answer298555.1Wrong answer243744.9Have you heard of an ethics review committee?Yes180333.3No361966.7Have you heard about the FDA?Yes400573.9No141726.1Does the general authority of food and drug administration have any role in CT policy?Yes443281.7No99018.3Are there any ethical guidelines to regulate CTs?YesNo485956389.610.4IS there direct benefit to the participants in CTs?Correct answer208538.5Wrong answer333761.5IS there a direct benefit to the community due to the people participating in CTs?Yes487689.9No54610.1When can the research team start a CTs?Correct answer325560.0Wrong answer216740.0Can the research team initiate the CT without consent of the participants?Yes5309.8No489290.2Are the participants free to withdraw from the CT at any time?Yes409975.6No132324.4Patients’ confidential information (such as name) can be disclosed in the published articles?Yes148427.4No393872.6Table 3Participants’ attitudes toward clinical trials: response breakdown (n = 5,442)ItemNumber (n)Percentage %Do you agree to test a new experimental non-approved drug on patients?Yes154828.6No387471.4Do you agree to test an already approved drug on patients?Yes386971.4No155328.6Do you agree to test a new experimental drug on healthy volunteers?Yes184234.0No358066.0Do you agree to test a new experimental drug on child patients?Yes110220.3No432079.7Do you agree to test an already approved drug on child patients?Yes318358.7No223941.3Are you willing to participate in a CTs?Yes88016.2No454283.8Do you want to know more about CT?Yes420977.6No121322.4What is your perception towards CT?Positive answer378069.7Negative answer164230.3Would you trust the research team which is conducting the CT?Yes304556,2No237743.8 Table 2Participants’ knowledge of clinical trials: response distribution and accuracy (n = 5,442)ItemsNumbers(N)Percentage (%)Have you ever heard about clinical trials (CT)?YesNO3445197763.536.5Definition of a CTCorrect answer298555.1Wrong answer243744.9Have you heard of an ethics review committee?Yes180333.3No361966.7Have you heard about the FDA?Yes400573.9No141726.1Does the general authority of food and drug administration have any role in CT policy?Yes443281.7No99018.3Are there any ethical guidelines to regulate CTs?YesNo485956389.610.4IS there direct benefit to the participants in CTs?Correct answer208538.5Wrong answer333761.5IS there a direct benefit to the community due to the people participating in CTs?Yes487689.9No54610.1When can the research team start a CTs?Correct answer325560.0Wrong answer216740.0Can the research team initiate the CT without consent of the participants?Yes5309.8No489290.2Are the participants free to withdraw from the CT at any time?Yes409975.6No132324.4Patients’ confidential information (such as name) can be disclosed in the published articles?Yes148427.4No393872.6 Participants’ knowledge of clinical trials: response distribution and accuracy (n = 5,442) Yes NO 3445 1977 63.5 36.5 Yes No 4859 563 89.6 10.4 Table 3Participants’ attitudes toward clinical trials: response breakdown (n = 5,442)ItemNumber (n)Percentage %Do you agree to test a new experimental non-approved drug on patients?Yes154828.6No387471.4Do you agree to test an already approved drug on patients?Yes386971.4No155328.6Do you agree to test a new experimental drug on healthy volunteers?Yes184234.0No358066.0Do you agree to test a new experimental drug on child patients?Yes110220.3No432079.7Do you agree to test an already approved drug on child patients?Yes318358.7No223941.3Are you willing to participate in a CTs?Yes88016.2No454283.8Do you want to know more about CT?Yes420977.6No121322.4What is your perception towards CT?Positive answer378069.7Negative answer164230.3Would you trust the research team which is conducting the CT?Yes304556,2No237743.8 Participants’ attitudes toward clinical trials: response breakdown (n = 5,442) Among the participants, 9.1% had an high level of knowledge about CTs, while 37.4% demonstrated moderate knowledge. Conversely, 53.4% had a low level of knowledge. In terms of attitudes, 11.2% of participants had an favorable attitude towards CTs, 18.3% showed a neutral attitude, and 70.5% had a unfavorable attitude score Fig. 1.Fig. 1Distribution of knowledge and attitude toward clinical trials among participants (n = 5,442) Distribution of knowledge and attitude toward clinical trials among participants (n = 5,442) A chi-square test revealed significant associations between knowledge scores and certain demographic factors. Knowledge scores were significantly associated with occupation (p < 0.001), education level (p < 0.001), presence of chronic disease (p < 0.001), and previous participation in health-related research (p < 0.001). No significant associations were found with other variables. The associations between participant characteristics and knowledge scores are detailed in Table 4.Table 4Relationship between participants’ characteristics and knowledge levels of clinical trials (n = 5,442)VariableKnowledgeTotalLow (n = 2897)Moderate (n = 2029)High (n = 496)P-valueUnmarried33261803(54.2)1223(36.8)300(9.0)Employment status (occupation)unemployed953572(60.0)317(33.3)64(6.7) < 0.001student19611120(57.1)684(34.9)157(8.0)private work1249619(49.6)500(40.0)130(10.4)government work1259586(46.5)528(41.9)145(11.5)Education leveluneducated8243(52.4)35(42.7)4(4.9) < 0.001secondary or less923629(68.1)253(27.4)41(4.4)university or more44172225(50.4)1741(39.4)451(10.2)Presence of any chronic diseaseNo44192408(54.5)1596(36.1)415(9.4) < 0.001Yes1003489(48.8)433(43.2)81(8.1)Previous participation in healthy researchNo41632423(58.2)1423(34.2)317(7.6) < 0.001Yes1259474(37.6)606(48.1)179(14.2) Table 4Relationship between participants’ characteristics and knowledge levels of clinical trials (n = 5,442)VariableKnowledgeTotalLow (n = 2897)Moderate (n = 2029)High (n = 496)P-valueUnmarried33261803(54.2)1223(36.8)300(9.0)Employment status (occupation)unemployed953572(60.0)317(33.3)64(6.7) < 0.001student19611120(57.1)684(34.9)157(8.0)private work1249619(49.6)500(40.0)130(10.4)government work1259586(46.5)528(41.9)145(11.5)Education leveluneducated8243(52.4)35(42.7)4(4.9) < 0.001secondary or less923629(68.1)253(27.4)41(4.4)university or more44172225(50.4)1741(39.4)451(10.2)Presence of any chronic diseaseNo44192408(54.5)1596(36.1)415(9.4) < 0.001Yes1003489(48.8)433(43.2)81(8.1)Previous participation in healthy researchNo41632423(58.2)1423(34.2)317(7.6) < 0.001Yes1259474(37.6)606(48.1)179(14.2) Relationship between participants’ characteristics and knowledge levels of clinical trials (n = 5,442) Similarly, attitude scores were significantly associated with age (p = 0.003), gender (p < 0.001), occupation (p < 0.001), presence of chronic illness (p < 0.001), and previous participation in health-related research (p < 0.001). No significant associations were observed with other variables. The associations between participant characteristics and attitude scores are presented in Table 5.Table 5Relationship between participants’ characteristics and attitude levels toward clinical Trials (n = 5,442)VariableAttitudeTotalunfavorable (n = 3821)Neutral(n = 995)favorable (n = 606)p-valueGenderMale20591323(64.3)443(21.5)293(14,2) < 0.001Female33632498(74.3)552(16.4)313(9,3)Marital statusMarried20961515(72.3)368(17.6)213(10.2)0.053Unmarried33262307(69.3)627(18.8)393(11.8)Employment status (occupation)unemployed953757(79.4)126(13.2)70(7.3) < 0.001student19611362(69.5)369(18.8)230(11.7)private work1249864(69.2)235(18.8)150(12.0)government work1259838(66.6)265(21.0)156(12.4)Presence of any chronic diseaseNo44193157(71.4)801(18.1)461(10.4) < 0.001Yes1003664(66.2)194(19.3)145(14.5) Table 5Relationship between participants’ characteristics and attitude levels toward clinical Trials (n = 5,442)VariableAttitudeTotalunfavorable (n = 3821)Neutral(n = 995)favorable (n = 606)p-valueGenderMale20591323(64.3)443(21.5)293(14,2) < 0.001Female33632498(74.3)552(16.4)313(9,3)Marital statusMarried20961515(72.3)368(17.6)213(10.2)0.053Unmarried33262307(69.3)627(18.8)393(11.8)Employment status (occupation)unemployed953757(79.4)126(13.2)70(7.3) < 0.001student19611362(69.5)369(18.8)230(11.7)private work1249864(69.2)235(18.8)150(12.0)government work1259838(66.6)265(21.0)156(12.4)Presence of any chronic diseaseNo44193157(71.4)801(18.1)461(10.4) < 0.001Yes1003664(66.2)194(19.3)145(14.5) Relationship between participants’ characteristics and attitude levels toward clinical Trials (n = 5,442) A multinomial logistic regression analysis was conducted to examine the associations between various factors and the levels of knowledge and attitudes towards CTs. in terms of knowledge, participants working in private or governmental sectors had significantly high knowledge compared to unemployed individuals (OR = 1.65, p = 0.007, and OR = 1.87, p < 0.001, respectively). Participants who had previously participated in health research were more likely to have high knowledge (OR = 2.92, p < 0.001). Those with chronic diseases were more likely to have moderate knowledge compared to healthy individuals (OR = 1.31, p < 0.001). Geographic differences also influenced knowledge levels, with Egyptian participants showing higher knowledge than those from Morocco (OR = 0.54, p = 0.003), while participants from Qatar had greater knowledge than those from Egypt (OR = 2.88, p < 0.001). Factors associated with knowledge about CTs are shown in Table 6.Table 6Association between demographic factors and knowledge levels of clinical trials (n = 5,442)Knowled ge gradePredictorEstimateSEZOdds ratiop - valueHigh—LowIntercept−3.024460.5792−5.22160.0486 <.001GenderMale—Female−0.003650.108−0.03380.99640.973CountryPalestine- Egypt0.051030.22650.22531.05240.822Bahrain—Egypt0.155740.16110.96661.16850.334Libya—Egypt−0.205270.229−0.89650.81440.37Qatar—Egypt1.05960.18775.64432.8852 <.001Sudan—Egypt0.031070.38250.08121.03160.935Saudi Arabia—Egypt−0.153130.1873−0.81750.8580.414UEA—Egypt0.205030.35390.57931.22760.562Morocco—Egypt−0.622740.2125−2.93030.53650.003Kuwait—Egypt−0.942380.4782−1.97080.38970.049Lebanon—Egypt−11.762698.97E-07−1.31e − 70.00000779 <.001Oman—Egypt0.195860.32950.59441.21640.552Somalia—Egypt−11.451139.68E-07−1.18e − 70.0000106 <.001Syria—Egypt0.209680.66660.31451.23330.753Tunisia—Egypt−0.822761.062−0.77470.43920.439Jordan—Egypt−0.125050.3982−0.31410.88250.753Yemen—Egypt0.15890.79790.19921.17220.842Iraq—Egypt0.123040.63980.19231.13090.848Algeria—Egypt−0.092280.796−0.11590.91180.908Age31—40–18—300.049170.16120.3051.05040.7641—60–18—300.124260.17480.71081.13230.47762–18—30−0.966581.94E-09−4.98e − 80.3804 <.001more than 60–18—300.204370.43690.46781.22680.64EducationSecondary or less—Uneducated−0.264170.5641−0.46830.76780.64University or more—Uneducated0.845470.54481.5522.32910.121Monthly incomeMiddle—No income−0.052620.1557−0.33790.94870.735High—No income−0.153650.1586−0.96860.85760.333Marital statusMarried- Unmarried−0.014540.1355−0.10730.98560.915OccupationStudent—unemployed0.13130.1790.73361.14030.463Private work—Unemployed0.503190.18712.68931.6540.007Governmental work—Unemployed0.627820.18633.37071.8735 <.001Presence of any chronic diseasesYes—No−0.065260.1418−0.46010.93680.645Previous participation in health researchYes—No1.0720.11169.60672.9212 <.001Moderate—LowIntercept−0.914770.2716−3.36770.4006 <.001GenderMale- Female−0.064480.0651−0.9910.93760.322CountryPalestine- Egypt−0.367650.1509−2.43670.69240.015Bahrain—Egypt0.150580.09581.57171.16250.116Libya—Egypt−0.537510.1475−3.6440.5842 <.001Qatar—Egypt0.254460.13211.92671.28980.054Sudan—Egypt0.042480.22440.18931.04340.85Saudi Arabia—Egypt0.009780.10510.0931.00980.926UEA—Egypt−0.104680.2267−0.46170.90060.644Morocco—Egypt−0.496890.1178−4.21890.6084 <.001Kuwait—Egypt−0.256050.2006−1.27610.77410.202Lebanon—Egypt−0.0310.4853−0.06390.96950.949Oman—Egypt0.026250.20250.12971.02660.897Somalia—Egypt0.298510.44990.66351.34790.507Syria—Egypt−0.150870.4499−0.33540.860.737Tunisia—Egypt−0.472060.523−0.90260.62370.367Jordan—Egypt0.212440.21231.00081.23670.317Yemen—Egypt−1.499010.7698−1.94720.22340.052Iraq—Egypt0.621980.32251.92831.86260.054Algeria—Egypt−0.263020.5022−0.52370.76870.6Age31—40–18—300.123010.09841.25011.13090.21141—60–18—300.047790.10640.44921.04890.65362–18—3012.968681.36E-08951,000,000428,771.394 <.001more than 60–18—300.253640.23131.09641.28870.273EducationSecondary or less—Uneducated−0.42740.2542−1.68160.65220.093University or more—Uneducated0.235880.24710.95441.2660.34Monthly incomeMiddle—No income−0.016690.0901−0.18520.98340.853High—No income0.019450.090.21611.01960.829Marital statusMarried- Unmarried−0.001390.0829−0.01680.99860.987OccupationStudent—unemployed0.174860.1011.73211.19110.083Private work—Unemployed0.374870.10643.52291.4548 <.001Governmental work—Unemployed0.476910.10774.42891.6111 <.001Presence of any chronic diseasesYes—No0.271590.08033.38151.312 <.001Previous participation in health researchYes—No0.731920.072710.06252.0791 <.001Data in bold are significant Table 6Association between demographic factors and knowledge levels of clinical trials (n = 5,442)Knowled ge gradePredictorEstimateSEZOdds ratiop - valueHigh—LowIntercept−3.024460.5792−5.22160.0486 <.001GenderMale—Female−0.003650.108−0.03380.99640.973CountryPalestine- Egypt0.051030.22650.22531.05240.822Bahrain—Egypt0.155740.16110.96661.16850.334Libya—Egypt−0.205270.229−0.89650.81440.37Qatar—Egypt1.05960.18775.64432.8852 <.001Sudan—Egypt0.031070.38250.08121.03160.935Saudi Arabia—Egypt−0.153130.1873−0.81750.8580.414UEA—Egypt0.205030.35390.57931.22760.562Morocco—Egypt−0.622740.2125−2.93030.53650.003Kuwait—Egypt−0.942380.4782−1.97080.38970.049Lebanon—Egypt−11.762698.97E-07−1.31e − 70.00000779 <.001Oman—Egypt0.195860.32950.59441.21640.552Somalia—Egypt−11.451139.68E-07−1.18e − 70.0000106 <.001Syria—Egypt0.209680.66660.31451.23330.753Tunisia—Egypt−0.822761.062−0.77470.43920.439Jordan—Egypt−0.125050.3982−0.31410.88250.753Yemen—Egypt0.15890.79790.19921.17220.842Iraq—Egypt0.123040.63980.19231.13090.848Algeria—Egypt−0.092280.796−0.11590.91180.908Age31—40–18—300.049170.16120.3051.05040.7641—60–18—300.124260.17480.71081.13230.47762–18—30−0.966581.94E-09−4.98e − 80.3804 <.001more than 60–18—300.204370.43690.46781.22680.64EducationSecondary or less—Uneducated−0.264170.5641−0.46830.76780.64University or more—Uneducated0.845470.54481.5522.32910.121Monthly incomeMiddle—No income−0.052620.1557−0.33790.94870.735High—No income−0.153650.1586−0.96860.85760.333Marital statusMarried- Unmarried−0.014540.1355−0.10730.98560.915OccupationStudent—unemployed0.13130.1790.73361.14030.463Private work—Unemployed0.503190.18712.68931.6540.007Governmental work—Unemployed0.627820.18633.37071.8735 <.001Presence of any chronic diseasesYes—No−0.065260.1418−0.46010.93680.645Previous participation in health researchYes—No1.0720.11169.60672.9212 <.001Moderate—LowIntercept−0.914770.2716−3.36770.4006 <.001GenderMale- Female−0.064480.0651−0.9910.93760.322CountryPalestine- Egypt−0.367650.1509−2.43670.69240.015Bahrain—Egypt0.150580.09581.57171.16250.116Libya—Egypt−0.537510.1475−3.6440.5842 <.001Qatar—Egypt0.254460.13211.92671.28980.054Sudan—Egypt0.042480.22440.18931.04340.85Saudi Arabia—Egypt0.009780.10510.0931.00980.926UEA—Egypt−0.104680.2267−0.46170.90060.644Morocco—Egypt−0.496890.1178−4.21890.6084 <.001Kuwait—Egypt−0.256050.2006−1.27610.77410.202Lebanon—Egypt−0.0310.4853−0.06390.96950.949Oman—Egypt0.026250.20250.12971.02660.897Somalia—Egypt0.298510.44990.66351.34790.507Syria—Egypt−0.150870.4499−0.33540.860.737Tunisia—Egypt−0.472060.523−0.90260.62370.367Jordan—Egypt0.212440.21231.00081.23670.317Yemen—Egypt−1.499010.7698−1.94720.22340.052Iraq—Egypt0.621980.32251.92831.86260.054Algeria—Egypt−0.263020.5022−0.52370.76870.6Age31—40–18—300.123010.09841.25011.13090.21141—60–18—300.047790.10640.44921.04890.65362–18—3012.968681.36E-08951,000,000428,771.394 <.001more than 60–18—300.253640.23131.09641.28870.273EducationSecondary or less—Uneducated−0.42740.2542−1.68160.65220.093University or more—Uneducated0.235880.24710.95441.2660.34Monthly incomeMiddle—No income−0.016690.0901−0.18520.98340.853High—No income0.019450.090.21611.01960.829Marital statusMarried- Unmarried−0.001390.0829−0.01680.99860.987OccupationStudent—unemployed0.174860.1011.73211.19110.083Private work—Unemployed0.374870.10643.52291.4548 <.001Governmental work—Unemployed0.476910.10774.42891.6111 <.001Presence of any chronic diseasesYes—No0.271590.08033.38151.312 <.001Previous participation in health researchYes—No0.731920.072710.06252.0791 <.001Data in bold are significant Association between demographic factors and knowledge levels of clinical trials (n = 5,442) Data in bold are significant Regarding attitudes, the presence of chronic diseases (OR = 1.35, p = 0.01) and previous participation in health research (OR = 2.01, p < 0.001) were significantly associated with favorable attitude levels. Males had a higher likelihood of a favorable attitude compared to females (OR = 1.59, p < 0.001). Participants aged 31 to 40 years had unfavorable attitude levels compared to those aged below 30 years (OR = 0.69, p = 0.014). Additionally, participants working in governmental sectors and students were more likely to have a neutral attitude compared to unemployed individuals (OR = 1.49, p = 0.004, and OR = 1.32, p = 0.03, respectively). Participants from Qatar and Libya had favorable attitude levels compared to those from Egypt (OR = 5.1, p < 0.001, and OR = 1.5, p = 0.04, respectively), while Egyptian participants showed favorable attitude levels than those from Palestine (OR = 0.657, p = 0.019) and Bahrain (OR = 0.648, p < 0.001). Factors associated with attitudes towards CTs are detailed in Table 7.Table 7Association Between Demographic Factors and Attitude Levels Toward Clinical Trials (n = 5,442)Attitude gradePredictorEstimateSEZOdds ratiop-valueGenderMale—Female0.461150.0964.8051.586 <.001CountryPalestine- Egypt−0.220030.2378−0.92520.8020.355Bahrain—Egypt−0.241550.1623−1.48810.7850.137Libya—Egypt0.404960.19932.03141.4990.042Qatar—Egypt1.630580.16499.88725.107 <.001Sudan—Egypt0.00610.3570.01711.0060.986Saudi Arabia—Egypt−0.017330.1658−0.10450.9830.917UEA—Egypt0.176190.33610.52421.1930.6Morocco—Egypt−0.119930.1904−0.62970.8870.529Kuwait—Egypt−0.486470.369−1.31840.6150.187Lebanon—Egypt−0.886441.0441−0.8490.4120.396Oman—Egypt0.32450.29751.09081.3830.275Somalia—Egypt0.17590.64510.27261.1920.785Syria—Egypt0.821280.5441.50972.2730.131Tunisia—Egypt1.057730.61231.72762.880.084Jordan—Egypt0.083650.33060.2531.0870.8Yemen—Egypt−0.07550.7751−0.09740.9270.922Iraq—Egypt0.709120.41991.68872.0320.091Algeria—Egypt0.166460.65630.25371.1810.8Age31—40–18—30−0.36880.1507−2.44680.6920.01441—60–18—30−0.312360.1653−1.89010.7320.05962–18—3012.862952.14E-0760,000,000385,752.739 <.001more than 60–18—300.007810.35660.02191.0080.983EducationSecondary or less—Uneducated−0.598760.3071−1.94970.5490.051University or more—Uneducated−0.476320.2944−1.61810.6210.106Monthly incomeMiddle—No income−0.154030.1397−1.10220.8570.27High—No income0.098010.13490.72671.1030.467marital status:Married—Unmarried−0.010620.1234−0.08610.9890.931OccupationStudent—unemployed0.237490.16321.45481.2680.146Private work—Unemployed0.271640.17411.56011.3120.119Governmental work—Unemployed0.310140.1751.77181.3640.076Presence of any chronic diseasesYes—No0.299040.11672.56211.3490.01Previous participation in health researchYes—No0.699260.10426.71322.012 <.001neutral—unfavorableIntercept−2.196950.3782−5.80880.111 <.001GenderMale—Female0.411070.07775.29241.508 <.001CountryPalestine- Egypt−0.42030.1799−2.33590.6570.019Bahrain—Egypt−0.434330.1183−3.67030.648 <.001Libya—Egypt−0.292630.1741−1.68060.7460.093Qatar—Egypt0.475830.1513.15071.6090.002Sudan—Egypt0.023570.25180.09361.0240.925Saudi Arabia—Egypt−0.520840.1343−3.87880.594 <.001UEA—Egypt0.141660.24980.56711.1520.571Morocco—Egypt−0.476230.1438−3.31150.621 <.001Kuwait—Egypt−0.290790.2375−1.22450.7480.221Lebanon—Egypt−1.058810.7626−1.38840.3470.165Oman—Egypt0.210870.2230.94561.2350.344Somalia—Egypt−0.969380.7588−1.27760.3790.201Syria—Egypt0.337920.48190.70131.4020.483Tunisia—Egypt0.186380.60440.30841.2050.758Jordan—Egypt−0.186750.2553−0.73150.830.464Yemen—Egypt−0.552450.6509−0.84880.5760.396Iraq—Egypt−0.284640.4292−0.66320.7520.507Algeria—Egypt−1.02120.7643−1.33620.360.181Age31—40–18—300.028850.11870.24311.0290.80841—60–18—30−0.077040.133−0.57940.9260.56262–18—30−1.273228.16E-09−1.56e − 80.28 <.001more than 60–18—300.165790.2850.58171.180.561EducationSecondary or less—Uneducated0.488230.35831.36261.6290.173University or more—Uneducated0.508970.35131.44891.6640.147Monthly incomeMiddle—No income−0.089150.1112−0.80150.9150.423High—No income−0.075630.1113−0.67960.9270.497Marital statusMarried—Unmarried0.020190.10150.19891.020.842OccupationStudent—unemployed0.277390.12912.14881.320.032Private work—Unemployed0.259320.1371.89221.2960.058Governmental work—Unemployed0.398440.13662.91721.490.004Presence of any chronic diseasesYes—No0.152250.0981.5531.1640.12Previous participation in health researchYes—No0.668020.08298.05461.95 <.001Data in bold are significant Table 7Association Between Demographic Factors and Attitude Levels Toward Clinical Trials (n = 5,442)Attitude gradePredictorEstimateSEZOdds ratiop-valueGenderMale—Female0.461150.0964.8051.586 <.001CountryPalestine- Egypt−0.220030.2378−0.92520.8020.355Bahrain—Egypt−0.241550.1623−1.48810.7850.137Libya—Egypt0.404960.19932.03141.4990.042Qatar—Egypt1.630580.16499.88725.107 <.001Sudan—Egypt0.00610.3570.01711.0060.986Saudi Arabia—Egypt−0.017330.1658−0.10450.9830.917UEA—Egypt0.176190.33610.52421.1930.6Morocco—Egypt−0.119930.1904−0.62970.8870.529Kuwait—Egypt−0.486470.369−1.31840.6150.187Lebanon—Egypt−0.886441.0441−0.8490.4120.396Oman—Egypt0.32450.29751.09081.3830.275Somalia—Egypt0.17590.64510.27261.1920.785Syria—Egypt0.821280.5441.50972.2730.131Tunisia—Egypt1.057730.61231.72762.880.084Jordan—Egypt0.083650.33060.2531.0870.8Yemen—Egypt−0.07550.7751−0.09740.9270.922Iraq—Egypt0.709120.41991.68872.0320.091Algeria—Egypt0.166460.65630.25371.1810.8Age31—40–18—30−0.36880.1507−2.44680.6920.01441—60–18—30−0.312360.1653−1.89010.7320.05962–18—3012.862952.14E-0760,000,000385,752.739 <.001more than 60–18—300.007810.35660.02191.0080.983EducationSecondary or less—Uneducated−0.598760.3071−1.94970.5490.051University or more—Uneducated−0.476320.2944−1.61810.6210.106Monthly incomeMiddle—No income−0.154030.1397−1.10220.8570.27High—No income0.098010.13490.72671.1030.467marital status:Married—Unmarried−0.010620.1234−0.08610.9890.931OccupationStudent—unemployed0.237490.16321.45481.2680.146Private work—Unemployed0.271640.17411.56011.3120.119Governmental work—Unemployed0.310140.1751.77181.3640.076Presence of any chronic diseasesYes—No0.299040.11672.56211.3490.01Previous participation in health researchYes—No0.699260.10426.71322.012 <.001neutral—unfavorableIntercept−2.196950.3782−5.80880.111 <.001GenderMale—Female0.411070.07775.29241.508 <.001CountryPalestine- Egypt−0.42030.1799−2.33590.6570.019Bahrain—Egypt−0.434330.1183−3.67030.648 <.001Libya—Egypt−0.292630.1741−1.68060.7460.093Qatar—Egypt0.475830.1513.15071.6090.002Sudan—Egypt0.023570.25180.09361.0240.925Saudi Arabia—Egypt−0.520840.1343−3.87880.594 <.001UEA—Egypt0.141660.24980.56711.1520.571Morocco—Egypt−0.476230.1438−3.31150.621 <.001Kuwait—Egypt−0.290790.2375−1.22450.7480.221Lebanon—Egypt−1.058810.7626−1.38840.3470.165Oman—Egypt0.210870.2230.94561.2350.344Somalia—Egypt−0.969380.7588−1.27760.3790.201Syria—Egypt0.337920.48190.70131.4020.483Tunisia—Egypt0.186380.60440.30841.2050.758Jordan—Egypt−0.186750.2553−0.73150.830.464Yemen—Egypt−0.552450.6509−0.84880.5760.396Iraq—Egypt−0.284640.4292−0.66320.7520.507Algeria—Egypt−1.02120.7643−1.33620.360.181Age31—40–18—300.028850.11870.24311.0290.80841—60–18—30−0.077040.133−0.57940.9260.56262–18—30−1.273228.16E-09−1.56e − 80.28 <.001more than 60–18—300.165790.2850.58171.180.561EducationSecondary or less—Uneducated0.488230.35831.36261.6290.173University or more—Uneducated0.508970.35131.44891.6640.147Monthly incomeMiddle—No income−0.089150.1112−0.80150.9150.423High—No income−0.075630.1113−0.67960.9270.497Marital statusMarried—Unmarried0.020190.10150.19891.020.842OccupationStudent—unemployed0.277390.12912.14881.320.032Private work—Unemployed0.259320.1371.89221.2960.058Governmental work—Unemployed0.398440.13662.91721.490.004Presence of any chronic diseasesYes—No0.152250.0981.5531.1640.12Previous participation in health researchYes—No0.668020.08298.05461.95 <.001Data in bold are significant Association Between Demographic Factors and Attitude Levels Toward Clinical Trials (n = 5,442) Data in bold are significant A Spearman's correlation was conducted to explore the relationship between total knowledge scores and total attitude scores. The analysis revealed a positive correlation between the two variables indicating that higher knowledge levels are associated with more favorable attitudes (p < 0.001). Discussion This study is unique as the initial assessment of knowledge and attitudes on cancer clinical trials in the MENA region, which is significantly underrepresented in clinical trial research, comprising less than 1% of global trials [17]. Our findings address significant information gaps essential for improving trial participation and strengthening regional research capabilities. By recognizing common obstacles and misconceptions, we seek to enhance activities that increase awareness and engagement in clinical research, so promoting a more vigorous research culture in the MENA area. Our research revealed that 63.5% of participants were aware of clinical trials, which closely corresponds with Abouelkheir et al. [12], where 64.3% of respondents were unaware of CTs. A significant majority (89.6%) of our participants acknowledged that clinical trials are regulated by ethical rules, consistent with the 82.9% reported by Abouelkheir et al. [12]. Nonetheless, a significant gap in understanding remains concerning the exact purpose of Institutional Review Boards (IRBs) or ethics review boards. This indicates that although participants typically recognize the existence of ethical oversight, many are unaware of the organizations tasked with protecting their interests, a difficulty also noted by Al-Rawashdeh et al. [18]. Addressing this deficiency is essential, as knowing the protective role of IRBs can foster confidence in clinical research methodologies. Our data demonstrates that 53.4% of participants possess limited understanding regarding clinical trials, highlighting a substantial awareness deficit. This aligns with prior studies, including Nair et al. [17], which indicated that 41.3% of participants were unaware of CTs, and Abouelkheir et al. [12], where 57.1% of respondents lacked knowledge about CTs. Knowledge levels were influenced by employment status and past research experience; participants employed in private or public sectors demonstrated superior knowledge compared to the unemployed. This indicates that labor engagement increases access to health information, hence improving comprehension. Moreover, participants with prior research experience exhibited superior understanding, supporting the idea that direct exposure enhances awareness [19]. Furthermore, our study revealed that knowledge scores were substantially correlated with many factors: occupation (p < 0.001), education level (p < 0.001), presence of chronic disease (p < 0.001), and prior involvement in health-related research (p < 0.001). Nonetheless, no substantial correlations were detected with other demographic characteristics. This aligns with findings from other literature. Abouelkheir et al. identified education degree as a significant determinant of knowledge regarding clinical trials (CTs), with a reported p-value of 0.031. Notably, they could not identify correlations with other sociodemographic factors, indicating that educational level may be a principal determinant of awareness regarding CTs [12]. Altaf et al. and Awwad et al. also noted that individuals with higher educational qualifications exhibited markedly superior understanding of clinical trials in comparison to those with lower educational levels [20, 21]. This pattern underscores the essential role of education in promoting awareness and comprehension of clinical research among populations. In contrast, research conducted by Al Rawashdeh et al. and Ahram et al. indicated that awareness of clinical trials was markedly correlated with many sociodemographic characteristics, such as age, gender, income, and employment position. Consistent with our findings, they also identified a substantial correlation between knowledge and prior involvement in health-related research, suggesting that direct experience improves comprehension [18, 22]. Possible variations between studies may stem from differences in settings, sociocultural contexts, and the tools used for data collection. These factors can influence how participants perceive and understand clinical trials, highlighting the need for tailored educational strategies that address the specific needs of diverse populations. Variations among research may arise from discrepancies in locales, sociocultural contexts, and the instruments employed for data collecting. These characteristics can affect participants' perceptions and comprehension of clinical trials, underscoring the necessity for customized training initiatives that cater to the distinct needs of varied populations. Concerning attitudes about CTs, merely 11.2% of subjects displayed an outstanding attitude, whilst 70.5% manifested low sentiments. This contrasts with Kearns et al. (2021), who found that 24% of participants exhibited favorable attitudes towards CTs, indicating cultural disparities in perceptions and awareness levels between the MENA region and other populations. The positive link between chronic diseases and attitudes towards CTs aligns with the findings of Kearns et al. (2021), which indicated that patients with cancer histories were more inclined to hold favorable opinions of CTs. This pattern suggests that knowledge of severe conditions may enhance willingness to participate in clinical trials [23]. Our study found that participants employed in governmental sectors or who were students exhibited more favorable sentiments regarding CTs than unemployed individuals. This data indicates that educational background and job security may affect attitudes towards medical research, as individuals in secure work are likely to have superior access to knowledge and resources pertaining to clinical trials. Notable geographical disparities were observed, with participants from Qatar and Libya exhibiting favorable attitude levels compared to those from Egypt. Egyptian individuals demonstrated more favorable sentiments compared to their Palestinian counterparts. The regional disparities underscore the significance of cultural environment in influencing perceptions of CTs, since local healthcare systems, educational initiatives, and outreach programs can profoundly affect awareness and attitudes [24]. Overall, these findings highlight that factors such as age, gender, education, and occupation play a major role in shaping how people view clinical research. However, our sample mainly included young, highly educated female participants, which may affect how broadly the findings can be applied. Since favorable attitudes were more common among younger and male participants, this imbalance might have led to an underestimation of the actual level of favorable attitudes in the wider population. Future research should aim for a more balanced representation across demographic groups to provide a clearer picture of public knowledge and attitudes toward cancer clinical trials. Strengths and limitations This study possesses several notable strengths. First, the use of an online questionnaire enabled data collection from a large and diverse population across multiple MENA countries, thereby enhancing the generalizability of the findings. The approach was also cost-effective and provided participants with the convenience of completing the questionnaire at their own pace. Furthermore, the inclusion of participants from different countries and backgrounds offers valuable insight into regional variations in knowledge and attitudes toward cancer clinical trials. Nevertheless, several limitations must be acknowledged. The use of convenience sampling may have introduced selection bias, as individuals who chose to participate could differ systematically from those who declined, potentially leading to over- or underestimation of awareness levels. In addition, the reliance on online recruitment may have excluded individuals without internet access or those less comfortable with technology, thereby limiting the representativeness of the sample. While the study encompassed a diverse group from multiple MENA nations, cultural and socioeconomic differences may not be fully captured, which could compromise the broader generalizability of the results. The reliance on self-reported data further raises the possibility of social desirability bias, with participants providing responses they perceived as more acceptable rather than reflecting their true views. Moreover, by targeting only literate individuals able to read and write, the study excluded the illiterate population, which may hold distinct perspectives or levels of awareness regarding clinical trials. Finally, although the questionnaire was adapted from validated tools, the use of a modified version may not have fully captured all dimensions of knowledge and attitudes toward clinical trials, potentially leaving gaps in understanding. Conclusion This multinational cross-sectional study highlights both awareness and significant knowledge gaps regarding cancer CTs among the general population in the MENA region. While a moderate level of familiarity with CTs exists, a substantial proportion of participants remain hesitant to engage, primarily due to misconceptions and insufficient information. These barriers emphasize the urgent need for targeted educational initiatives and public awareness campaigns to enhance understanding and foster favorable attitudes toward clinical trial participation. To bridge these gaps, educational strategies should incorporate evidence-based curricula, interactive seminars, online courses, and community outreach programs. Public awareness efforts must prioritize clear, accessible communication through simplified language, visual aids, and engagement via social and traditional media. Additionally, patient advocacy initiatives can play a vital role in building trust and dispelling misinformation. Practical considerations should focus on ensuring informed consent and transparency, improving accessibility through multilingual and literacy-appropriate materials, and simplifying participation logistics. By addressing these challenges, healthcare systems in the MENA region can enhance public engagement in clinical research, facilitating the development of novel cancer therapies and ultimately improving patient outcomes. Regular feedback and impact assessments will be essential to refining these initiatives and ensuring their long-term effectiveness. This study represents a pivotal step toward strengthening clinical research literacy and participation, contributing to improved healthcare practices and patient care in the region.